Molecular basis for targeting Caveolin-1 in multiple myeloma therapy

Cav-1 is a context-dependent therapeutic vulnerability in MM. Blocking Cav-1 can restore drug sensitivity, reduce protection from the bone marrow environment, and improve immune killing of tumor cells. Given the multifaceted nature of Cav-1 and its prevalence in normal tissues, the development of selective or tumor-targeted delivery mechanisms is imperative. New strategies, including inhibitors and nanoparticle delivery, combined with biomarker-guided patient selection, may offer safe and effective targeting of Cav-1 and support combination treatments for resistant MM.